Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome

NCT03070574 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped Due to poor patient recruitment and insufficient financing.

Conditions

Colorectal Cancer

Interventions

DRUG: mesalamine 2400 MG (5-ASA)
DRUG: mesalamine 1200 MG
OTHER: Placebo

Sponsor

Christoph Gasche

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]